Biologic drug reduces symptoms, hospitalization for severe pulmonary hypertension after diagnosis

Results of the phase 3 clinical trial suggest benefits for early treatment

5:00 AM

Author | Noah Fromson

heart graphic navy and yellow
Jacob Dwyer, Justine Ross, Michigan Medicine

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within the first year after diagnosis, according to a study published in the New England Journal of Medicine.

Within the first year of receiving a pulmonary arterial hypertension diagnosis, patients who took sotatercept, in addition to standard-of-care therapy, reduced the risk experiencing deterioration in health — such as less ability to exercise, worsening symptoms and unplanned hospitalizations — by 76%.

Investigators for the Phase 3 clinical trial detected positive results for patients after just three doses of the injectable medication, which sold under the brand name Winrevair.

Results were presented at the 2025 European Respiratory Society Congress in Amsterdam.

“These results are incredibly promising for patients early in their journey with pulmonary arterial hypertension, which still has limited treatment options,” said first author Vallerie V. McLaughlin, M.D., the Kim A. Eagle Endowed Professor of Cardiovascular Medicine at University of Michigan Medical School.

McLaughlin, who directs the Pulmonary Hypertension Program at the U-M Health Frankel Cardiovascular Center, was the lead investigator of the double-blind, placebo-controlled HYPERION study.

The clinical trial concluded early due to loss of clinical equipoise, meaning researchers felt they could not ethically continue the study due to overwhelmingly positive results for patients on sotatercept compared to placebo in recent sotatercept randomized, controlled trials.

“PAH is a chronic, progressive condition with high morbidity and mortality, and many patients present at advanced stages of disease,” McLaughlin said.

“Our findings suggest early treatment with sotatercept may help patients to achieve and maintain a lower risk status and improve outcomes.”

Sotatercept is approved by the U.S. Food and Drug Administration for treatment of adults with pulmonary arterial hypertension, or PAH, and is offered in concert with standard-of-care therapies.

The medication offers a novel approach by targeting proteins called activins.

In PAH, elevated activin signaling can eventually thicken the pulmonary arteries, putting extra work on the heart to pump blood to the lungs.

Past studies of sotatercept showed benefits for patients with high risk as well as those with longstanding pulmonary arterial hypertension.

The initial trial, STELLAR, found that patients taking the medication had improved capacity for exercise.

The  ZENITH trial demonstrated a decreased risk of death, hospitalization and lung transplantation in those at high risk of mortality.

Patients in both studies had a diagnosis of PAH for an average of seven to eight years. HYPERION extends to evidence base to patients diagnosed within one year.

Fewer than 2% of participants taking sotatercept in the HYPERION trial were hospitalized for worsening PAH symptoms, compared to 8.8% of the placebo group.

The most common adverse events reported with sotatercept were nosebleeds and spider veins.

“The positive effects of adding sotatercept to standard therapy in patients with PAH are remarkable,” said Victor M. Moles, M.D., HYPERION investigator and clinical associate professor of internal medicine-cardiology at U-M Medical School.

“The results from the HYPERION trial underscore the critical importance of early intervention, demonstrating that earlier treatment leads to better outcomes.”

Additional authors: For a complete list of HYPERION investigators, view the supplementary appendix in the study.

Funding/disclosures: This study was funded by Merck Sharp & Dohme, a subsidiary of Merck. The study analyses presented here were funded by Merck Sharp & Dohme, a subsidiary of Merck.

Paper cited: “Sotatercept for Pulmonary Arterial Hypertension within the First Year of Diagnosis,” New England Journal of Medicine. DOI: 10.1056/NEJMoa2508170

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week.

Sign up for the Health Lab Podcast. Add us wherever you listen to your favorite shows.  


More Articles About:

Cardiovascular: Diseases & Conditions Cardiovascular: Treatment & Surgery Lungs and Breathing Cardiopulmonary Care Heart Failure Drug Discovery All Research Topics
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

profile-vallerie-mclaughlin-2023

Vallerie McLaughlin

Professor

Related

Health Lab

Why Does Pulmonary Hypertension Cause Shortness of Breath?

Catching one’s breath after mild or no activity could be a sign of a rare but serious condition affecting the body’s ability to circulate oxygenated blood to the heart.

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Alarm clock sitting on a white dinner plate with blue and yellow flowers on the rim and a fork and knife positioned on either side of the plate.
Health Lab

Intermittent fasting can reverse diabetes in mice, study finds

Study shows intermittent fasting and meal timing can help reverse type 2 diabetes by resting pancreatic beta cells
A man sits on a large red tractor. Behind him a bunch of corn is stacked in the back of the vehicle
Health Lab

Michigan man undergoes complex heart repair after last minute surgery cancelation

A complex operation at U-M Health enabled surgeons to remove scar tissue surrounding Scott Roach's heart and successfully repair his failing mitral valve.
Mother sits on a couch with a laptop on her lap while an elementary school age boy sits next to her playing on a tablet device.
Health Lab

New questionnaire aims to improve understanding of demand avoidance in children, teens

Pathological demand avoidance is a pattern of intense distress and avoidance of demands in children. A new questionnaire from University of Michigan researchers creates a structured way to assess these behaviors.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.